Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2

Dong, Shuang; Luo, Chenggang; Hu, Xuebo; Zhang, Jing; Cai, Qian; Yu, Qian; Ran, Fengming; Ou, Weihua; Wang, Jun; Huang, Qing; Ren, Tianhua; Hân, Gia; Zhang, Feng; Wei, Wei; Liang, Xiaofeng; Xu, Huiting; Wang, Sheng; Shi, Lei; Wei, Shaozhong; Sheng, Hu

doi:10.3389/fonc.2020.01555

Cited by 5 publications

(3 citation statements)

References 81 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COVID-19 has revolutionized healthcare worldwide, with unprecedented impact on cancer care. Clinical practice has substantially changed with the implementation of protective and preventive measures 15 . In most cases, during the first wave of COVID-19 pandemic, routine oncology care for metastatic cancer patients has been maintained without significant difference before and after the COVID-19 outbreak 16 .…”

mentioning

confidence: 99%

Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave

Indini

Pinotti²,

Artioli

et al. 2021

European Journal of Cancer

View full text Add to dashboard Cite

The novel Coronavirus Disease 2019 (COVID-19) pandemic has been an overwhelming challenge for worldwide health systems. Since the beginning of year 2020, COVID-19 has represented a potential harm for cancer patients and has often hindered oncology care. The Collegio Italiano dei Primari Oncologi Medici (CIPOMO) is an Italian association of head physicians in oncology departments, which promotes working and research activities in oncology on a national basis. During the second wave of COVID-19 pandemic, the CIPOMO promoted a national survey aiming to evaluate the impact of COVID-19 on oncologists’ clinical activity and what changes have been made compared with the Italian situation during the first wave of the pandemic. Overall, 138 heads of medical oncology departments participated in this survey: 75 (54%) from the North, 24 (17%) from the Center, and 39 (28%) from the South of Italy and islands. This survey provides an overview of Italian oncologists facing the second wave of COVID-19 pandemic. The lesson learned during the first wave of COVID-19 pandemic has led to a better organization of clinical activities, and regular testing among healthcare practitioners, with better chances to grant patients’ protection. However, the lack of standardized informatic platforms results in serious challenges in replacing frontal visits, often making a concrete reduction of patients’ hospital accesses unfeasible. Oncologists need to keep preserving the continuum of care of patients. Standardization of safety measures, together with the implementation of informatic platforms, can significantly improve oncology pathways during this second wave of COVID-19 pandemic.

show abstract

mentioning

confidence: 99%

Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave

Indini

Pinotti²,

Artioli

et al. 2021

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Moreover, the current coronavirus disease (COVID-19) pandemic ( To et al, 2021 ) represents a considerable threat to human life and has resulted in a high proportion of death worldwide. COVID-19, caused by SARS-CoV-2, was first named by the National Health Commission as novel coronavirus pneumonia ( Dong et al, 2020 ), before being termed COVID-19 by the World Health Organization (WHO). The transmission route of the virus is similar to that of influenza, occurring mainly through the respiratory tract ( Ahn et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Investigation into the in vivo mechanism of diosmetin in patients with breast cancer and COVID-19 using bioinformatics

Wang

Long

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Patients with breast cancer are prone to SARS-CoV-2 infection [the causative virus of coronavirus disease (COVID-19)] due to their lack of immunity. In the current study, we examined the mechanism of action of Diosmetin, a flavonoid with anti-inflammatory properties, in patients with BRCA infected with SARS-CoV-2.We used bioinformatics technology to analyze the binding ability, biological function, and other biological characteristics of Diosmetinin vivo and examine the core target and potential mechanism of action of Diosmetin in patients with patients with breast cancer infected with SARS-CoV-2. A prognostic model of SARS-COV-2–infected breast cancer patients was constructed, and the core genes were screened out, revealing the correlation between these core genes and clinicopathological characteristics, survival rate, and high-risk and low-risk populations. The docking results revealed that Diosmetin binds well to the core genes of patients with breast cancer with COVID-19. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses suggested that Diosmetin inhibited inflammation, enhanced immune function, and regulated the cellular microenvironment in patients with BRCA/COVID-19. For the first time, we reveal the molecular functions and potential targets of Diosmetin in patients with breast cancer infected with SARS-CoV-2, improving the reliability of the new drug and laying the foundation for further research and development.

show abstract

“…Recent studies indicated that patients with cancer might be a vulnerable group, which had a higher risk of COVID-19 infection and a poorer prognosis than individuals without cancers. [4][5][6] It was reported that the fatality rate reached 5.6% among cancer patients compared with 2.3% in the general population. 7 Thus, more intensive attention should be paid to patients with cancer for avoiding rapid deterioration.…”

Section: Introductionmentioning

confidence: 99%

<p>Clinical Features and Short-Term Outcomes in COVID-19-Infected Patients with Cancer</p>

Wang¹,

Shan²,

Shen

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) is an infectious disease that has been spreading very fast worldwide. Up to now, there is scarce information regarding the clinical features and short-term outcomes of infected patients with cancer. Methods: We performed a retrospective study in Wuhan Union Hospital from Feb 14, 2020, to Mar 15, 2020, China. Data were retrieved including demographic and clinical features, laboratory findings, and outcome data. Patients were classified into the discharged group and undischarged group by the 4-week outcomes from admission. Difference analysis and correlation analysis were performed between the two groups. Results: A total of 37 patients were enrolled in the study, including 27 cancer survivors in routine follow-up. Breast cancer (18.9%) was the most frequent cancer type, and common symptoms included cough (54.1%), fever (48.6%), and fatigue (27%). Lymphocytopenia and hypoproteinemia were much frequent in patients who had received chemotherapy, radiotherapy, or surgery within the past month. However, the concentration of D-dimer (median: 3.75 vs 0.43, P =0.010) and fibrin degradation products (median: 23.60 vs 1.80, P =0.002) were evidently increased in this population compared with cancer survivors. At the end of follow-up, 83.8% of the enrolled patients were discharged. Among the discharged, women (48.6%) and cancer survivors (67.6%) showed better short-term outcomes. The elevated level of FDP was significantly higher in the undischarged group (median: 21.85 vs 2.00, P =0.049). The proportion of CD3-positive lymphocyte cells and CD4-positive lymphocytes was correlated with short-term outcomes. Conclusion: Peripheral lymphocyte subset (CD3-positive and CD4-positive) on admission as a novel biomarker had a potential association with early efficacy. Cancer survivors in routine follow-up would achieve better short-term outcomes. COVID-19 patients with cancer should gain more attention and close monitoring.

show abstract

Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2

Cited by 5 publications

References 81 publications

Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave

Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave

Investigation into the in vivo mechanism of diosmetin in patients with breast cancer and COVID-19 using bioinformatics

<p>Clinical Features and Short-Term Outcomes in COVID-19-Infected Patients with Cancer</p>

Contact Info

Product

Resources

About